Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Patricia Lapitan
Observed names:
P. Lapitan,
PATRICIA LAPITAN
Institutions:
University of Manchester,
Wythenshawe Hospital
Observed institutions:
Institute of Cancer Research,
University of Manchester,
National Cancer Institute,
Wythenshawe Hospital,
Division of Cancer Epidemiology and Genetics,
University College London,
Imperial College London
show all 7
OpenAlex ID:
A5104664210
Renal Cell Cancer – Insights in Drug Resistance Mechanisms
2023
·
HALIMA AWEYS
, DEISHA LEWIS
, et al.
·
Anticancer Research
·
78
PDF
Trends in Cancer Incidence in Younger and Older Adults: An International Comparative Analysis
2025
·
Amy Berrington de Gonzalez
, Martina Brayley
, et al.
·
Annals of Internal Medicine
·
32
PDF
Antibody Drug Conjugates in Urological Cancers: A Review of the Current Landscape
2024
·
Aruni Ghose
, Patricia Lapitan
, et al.
·
Current Oncology Reports
·
18
PDF
Precision oncology through next generation sequencing in hepatocellular carcinoma
2025
·
Sayali Shinde
, Carola Maria Bigogno
, et al.
·
Heliyon
·
12
Ethnicity-based comparative analysis of treatment endpoints of 30,000 HR+/HER2− metastatic breast cancer patients on CDK4/6 inhibitors (palbociclib/ribociclib/abemaciclib).
2026
·
Olivia Benny
, Adan Khan
, et al.
·
Journal of Clinical Oncology
PDF
461P Ethnicity-based comparative analysis of adverse effects in 30,000 HR+/HER2− metastatic breast cancer patients treated with CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib): A real-world meta-analysis
2026
·
O. Benny
, I. Mukherjee
, et al.
·
ESMO Open
460eP Ethnicity-based comparative analysis of progression free survival in 30,000 HR+/HER2− metastatic breast cancer patients treated with CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib): A real-world meta-analysis
2026
·
O. Benny
, J.K. Tan
, et al.
·
ESMO Open
475eP Ethnicity-based comparative analysis of objective response rate in 30,000 HR+/HER2− metastatic breast cancer patients treated with CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib): A real-world meta-analysis
2026
·
O. Benny
, V. Urs
, et al.
·
ESMO Open
473eP Ethnicity-based comparative analysis of overall survival in 30,000 HR+/HER2− metastatic breast cancer patients treated with CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib): A real-world meta-analysis
2026
·
O. Benny
, A.R. James
, et al.
·
ESMO Open
PDF
Show more works
View as search
Works count:
9
Citation count:
140
H-index:
4
I10-index:
4
Year
Topic
Type